Among the wave of guidance documents issued by the U.S. Food and Drug Administration (“FDA” or the “Agency”) in the first week of 2025 were ...

Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for ...

The expansion is a natural progression for Upperton who already develops and manufactures small molecule and biological, ...

The DSA segment offers early and in vivo discovery services for the identification and validation ... bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment ...

Leading UK contract development and manufacturing organisation (CDMO) Upperton Pharma Solutions, has completed the build of ...

UK contract development and manufacturing organization Upperton Pharma Solutions has completed the build of its new sterile ...

In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...

ValGenesis Inc., the market leader in enterprise validation lifecycle management systems (VLMS), and Compliance Group (CG), a quality excellence and regulatory compliance solutions provider based in ...

Where can researchers look for a beacon of hope amid trying times in the pharmaceutical industry? Read on for answers.

The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...

The union health ministry on 6 January reported 2 cases of HMPV in Karnataka detected by ICMR during routine surveillance.

VectorBuilder's partner, Ucello, announced that its CD19-targeting umbilical cord blood-derived allogeneic CAR-T cell therapy, UC101, received Investigational New Drug (IND) approval from the U.S.